Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Sanofi-aventis announces the termination of development and commercialization agreement for S-1 with Taiho Pharmaceutical

22 Jul 2008 - Sanofi-aventis announced that it is returning its territory rights to Taiho Pharmaceutical Co., Ltd. Japan for the development and commercialization of the oral anticancer agent S-1.
 
This termination follows the announcement by Taiho Pharmaceutical Co., Ltd of the Phase III study results which evaluated the efficacy and safety of the oral anti-cancer agent S-1 in a multicentric trial in patients with locally advanced gastric cancer.
 
S-1 is an oral fluorouracil anticancer product that combines 3 pharmacological agents: tegafur which is a pro-drug of 5 fluoro-uracil; gimeracil (5-chloro-2,4 dihydropyridine (CDHP)) which inhibits dihydropyrimidine dehydrogenase (DPD) enzyme activity; and oteracil (potassium oxonate (Oxo)) a gastrointestinal side effects corrector.
 
S-1 has been commercialized in Japan by Taiho Pharmaceutical since 1999 for the treatment of gastric, colorectal, head and neck, non-small cell lung, metastatic breast and pancreas cancers.